Related Experiment Video
Updated: Apr 5, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Identifying new targets in leukemogenesis using computational approaches
Archana Jayaraman1, Kaiser Jamil2, Haseeb A Khan3
1Centre for Biotechnology and Bioinformatics, School of Life Sciences, Jawaharlal Nehru Institute of Advanced Studies (JNIAS), Secunderabad, Telangana, India ; Center for Biotechnology, Jawaharlal Nehru Technological University (JNTUH), Kukatpally, Hyderabad, Telangana, India.
Abstract:
There is a need to identify novel targets in Acute Lymphoblastic Leukemia (ALL), a hematopoietic cancer affecting children, to improve our understanding of disease biology and that can be used for developing new therapeutics. Hence, the aim of our study was to find new genes as targets using in silico studies; for this we retrieved the top 10% overexpressed genes from Oncomine public domain microarray expression database; 530 overexpressed genes were short-listed from Oncomine database. Then, using prioritization tools such as ENDEAVOUR, DIR and TOPPGene online tools, we found fifty-four genes common to the three prioritization tools which formed our candidate leukemogenic genes for this study. As per the protocol we selected thirty training genes from PubMed. The prioritized and training genes were then used to construct STRING functional association network, which was further analyzed using cytoHubba hub analysis tool to investigate new genes which could form drug targets in leukemia. Analysis of the STRING protein network built from these prioritized and training genes led to identification of two hub genes, SMAD2 and CDK9, which were not implicated in leukemogenesis earlier. Filtering out from several hundred genes in the network we also found MEN1, HDAC1 and LCK genes, which re-emphasized the important role of these genes in leukemogenesis. This is the first report on these five additional signature genes in leukemogenesis. We propose these as new targets for developing novel therapeutics and also as biomarkers in leukemogenesis, which could be important for prognosis and diagnosis.
Insights
Researchers identified novel drug targets for childhood Acute Lymphoblastic Leukemia (ALL) by analyzing gene expression data. This study proposes five new signature genes, including SMAD2 and CDK9, as potential therapeutic targets and biomarkers for ALL.
Area of Science:
- Oncology
- Bioinformatics
- Genetics
Background:
- Acute Lymphoblastic Leukemia (ALL) is a common childhood cancer requiring novel therapeutic targets.
- Understanding ALL's molecular biology is crucial for developing new treatments.
- Current therapeutic strategies necessitate the identification of new drug targets.
Purpose of the Study:
- To identify novel genes as potential therapeutic targets for Acute Lymphoblastic Leukemia (ALL) using in silico methods.
- To discover new biomarkers for prognosis and diagnosis in ALL.
- To investigate the role of specific genes in leukemogenesis.
Main Methods:
- Utilized the Oncomine database to retrieve the top 10% overexpressed genes in ALL.
- Employed prioritization tools (ENDEAVOUR, DIR, TOPPGene) to shortlist candidate leukemogenic genes.
- Constructed a STRING functional association network and analyzed it with cytoHubba for hub gene identification.
Main Results:
- Identified SMAD2 and CDK9 as novel hub genes not previously implicated in leukemogenesis.
- Confirmed the role of MEN1, HDAC1, and LCK in leukemogenesis.
- Reported five additional signature genes in leukemogenesis for the first time.
Conclusions:
- Proposed SMAD2, CDK9, MEN1, HDAC1, and LCK as novel therapeutic targets for ALL.
- Suggested these identified genes as potential biomarkers for ALL prognosis and diagnosis.
- Highlighted the potential for developing new targeted therapies and improving patient outcomes in ALL.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

